SINAPPS2 is a phase II ongoing clinical trial aiming to test the efficacy and safety of immunotherapy (intravenous immunoglobulin combined with rituximab) vs placebo treatment in people with acute symptoms of psychosis and anti-neuronal membrane antibodies.
More information here.
Tests for antibodies in psychosis
We are offering tests for antibodies in people experiencing psychotic symptoms through the Prevalence of Pathogenic Autoantibodies in Psychosis study (PPiP2)
Those who may be eligible to take part in our study will be:
- Experiencing a current first episode of psychosis lasting less than 2 years. This can be a first episode or relapse
- 18-70 years
If this is you or someone you know who is receiving treatment from an NHS Mental Health Trust, details of who to contact in your local area are listed here. This will enable you to contact the relevant PPiP2 Study Team.
If the treating trust is not listed but you or someone you know meets of eligibility criteria then your/their clinician (GP/psychiatrist) can request the antibodies blood test if they feel it is clinically indicated.
The particular antibodies we recommend they test for are NMDAR -live assay, LGI1. The details for how clinicians can request the test and the request card to use are here: